RT Journal Article
SR Electronic
T1 Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.05.23291954
DO 10.1101/2023.07.05.23291954
A1 Bennett, Chijioke
A1 Rivers, E Joy
A1 Woo, Wayne
A1 Bloch, Mark
A1 Cheung, King
A1 Griffin, Paul
A1 Mohan, Rahul
A1 Deshmukh, Sachin
A1 Arya, Mark
A1 Cumming, Oscar
A1 Neville, A. Munro
A1 Pardey, Toni McCallum
A1 Plested, Joyce S
A1 Cloney-Clark, Shane
A1 Zhu, Mingzhu
A1 Kalkeri, Raj
A1 Patel, Nita
A1 Buchanan, Agi
A1 Marcheschi, Alex
A1 Swan, Jennifer
A1 Smith, Gale
A1 Cho, Iksung
A1 Glenn, Gregory M.
A1 Walker, Robert
A1 Mallory, Raburn M.
YR 2023
UL http://medrxiv.org/content/early/2023/07/06/2023.07.05.23291954.abstract
AB Background Mutations present in emerging SARS-CoV-2 variants permit evasion of neutralization with prototype vaccines. A novel Omicron BA.1 subvariant-specific vaccine (NVX-CoV2515) was tested alone, or as a bivalent preparation in combination with the prototype vaccine (NVX-CoV2373), to assess antibody responses to SARS-CoV-2.Methods Participants aged 18 to 64 years immunized with 3 doses of prototype mRNA vaccines were randomized 1:1:1 to receive a single dose of NVX-CoV2515, NVX-CoV2373, or bivalent mixture in a phase 3 study investigating heterologous boosting with SARS-CoV-2 recombinant spike protein vaccines. Immunogenicity was measured 14 and 28 days after vaccination for the SARS-CoV-2 Omicron BA.1 sublineage and ancestral strain. Safety profiles of vaccines were assessed.Results Of participants who received trial vaccine (N=829), those administered NVX-CoV2515 (n=286) demonstrated superior neutralizing antibody response to BA.1 versus NVX-CoV2373 (n=274) at Day 14 (geometric mean titer ratio [95% CI]: 1.6 [1.33, 2.03]). Seroresponse rates [n/N; 95% CI] were 73.4% [91/124; 64.7, 80.9] for NVX-CoV2515 versus 50.9% [59/116; 41.4, 60.3] for NVX-CoV2373. All formulations were similarly well-tolerated.Conclusions NVX-CoV2515 elicited a superior neutralizing antibody response against the Omicron BA.1 subvariant compared with NVX-CoV2373 when administered as a fourth dose. Safety data were consistent with the established safety profile of NVX-CoV2373.Competing Interest StatementCB, EJR, WW, JSP, SCC, MZ, RK, NP, AB, AM, JS, GS, IC, GMG, RW, and RMM are current or former Novavax employees and as such receive or received a salary for their work, and may hold Novavax stock. OC and TMP act as investigators at Novatrials on clinical trials and have not received personal financial payment from Novavax. AMN acts an investigator at AusTrials on clinical trials of COVID-19 and other vaccines sponsored by vaccine manufacturers, including Pfizer, GlaxoSmithKline, Novavax, Seqirus and Moderna. He receives no personal financial payment for this work. KC acts as an investigator at Emeritus Research and has not received any personal financial payment from Novavax. RM acts as an investigator at Paratus Clinical Research and has not received any personal financial payment from Novavax. MB has received payment or honoraria as well as support for meeting attendance and/or travel from Gilead Sciences and ViiV Healthcare, and has received research funding from Gilead Sciences, ViiV Healthcare, GlaxoSmithKline, Merck & Co, Eli Lilly, Amgen, Pfizer, Bristol-Myers Squibb, Novartis, and Sanofi. He has also participated on a data safety monitoring board or advisory board for Gilead Sciences, ViiV Healthcare, and Cymra. MA, PG, and SD report no conflicts of interest.Clinical TrialThis study is registered at clinicaltrials.gov: NCT05372588Funding StatementThis work was supported by Novavax, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committees/IRFs of the Alfred Hospital Ethics Committee (Melbourne, Victoria, Australia) and the Bellberry Human Research Ethics Committee (Adelaide, South Australia) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesStudy information is available at https://clinicaltrials.gov/ct2/show/NCT05372588, and requests will be considered.https://clinicaltrials.gov/ct2/show/NCT05372588